#$%^&*AU2016238874A120161027.pdf#####Abstract Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described, herein. 2914591v15 / 35 3200 0 Body weight 2800 - DMSO (U) 2 2400 0 2.5 mg/kg (a) E 0. 2000 >；10ays 61.0 % 5 mg/kg (A) E S12007.5 mg/kg (+) 800400 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 S.C. Cell i.p. drug Days injection injection Figure 8 320030, Body weight DMSO (M) 28002400E o 2000-o 6 _______________57.0% S6 10 1 1 16 2D 426 7.5 mg/kg (A) 1600-Dy 1200 5 mg/kg (a) S12008004000 2 4 6 8 10 12 14 16 18 20 22 24 26 +~D ays S.C. cell i.p. drug injection injection Figure 9
